thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
== Availability == Chlordiazepoxide is available in various dosage forms, alone or in combination with other drugs, worldwide. In combination with clidinium as NORMAXIN-CC and in combination with dicycloverine as NORMAXIN for IBS, and with the tricyclic antidepressant amitriptyline as Limbitrol.
=== Pharmacokinetics === When taken by mouth, canagliflozin reaches highest blood plasma concentrations after one to two hours and has an absolute bioavailability of 65%, independently of food intake. When in the bloodstream, 99% of the substance are bound to plasma proteins, mainly albumin. It is metabolized mainly by O-glucuronidation via the enzymes UGT1A9 and UGT2B4, and by hydroxylation to a lesser extent. The terminal half life is 10.6 hours for a 100 mg dose and 13.1 hours for a 300 mg dose, with 43% being excreted in the faeces (mostly in unchanged form) and 33% in the urine (mostly as glucuronide).
== Impact of narcotics trafficking == In the late 1980s, there continued to be concern about an overburdened and allegedly corrupt judicial system. According to the Department of State's Country Reports on Human Rights Practices for 1988 and Bolivian press reports, judges were implicated in drug-related corruption. Narcotics traffickers routinely tried to bribe judicial and other officials in exchange for releasing suspected smugglers, returning captured drugs, and purging incriminating files. In 1988 the Senate's Constitution and Justice Committee ordered the suspension of thirteen judges of the La Paz, Cochabamba, and Santa Cruz superior district courts of justice for wrongdoing in drug-trafficking cases. The Supreme Court of Justice insisted, however, on its prerogative to try the judges first. After doing so, it ordered the suspension of several of the accused judges and continued to investigate others. Relatively few prosecutions or forfeitures of traffickers' assets took place. A lack of judicial investigatory power hampered the investigation of the bank accounts and the origin of wealth of people suspected of trafficking in drugs. Although thirteen of the "big bosses" reportedly had been identified by early 1988, arrests of drug kingpins were infrequently reported because of lack of evidence.
== Manufacturing == PRP is prepared by taking blood from the person, and then putting it through centrifugation designed to separate PRP from platelet-poor plasma and red blood cells. This is usually done in the clinic, using commercially available kits and equipment. The resulting substance varies from person to person and from facility to facility.
In 1993, the FDA issued a document for the content limits of DON in food and animal feed at an advisory level. In 2003, US published a patent that is very promising for farmers to produce a trichothecene-resistant crop. Zearalenone Zearalenols
Sources: en.wikipedia.org
After a short career break, he returned to work in 1978, appearing in two stage productions: 1978's The Mighty Gents, winning a Drama Desk Award and a Clarence Derwent Award for his role as a wino, and White Pelicans. Freeman continued to work in theater and a year later, appeared in the Shakespearean tragedies Coriolanus, receiving the Obie Award in 1980 for the title role as well as Julius Caesar. In 1980, he had a small role as Walter in the drama Brubaker, which starred Robert Redford as a prison warden. Freeman next appeared in the television film, Attica (1980), which is about the 1971 Attica Prison riot and its aftermath. A year later he had a lead role in Peter Yates' Eyewitness with co-stars William Hurt and Sigourney Weaver. From 1982 to 1984, Freeman was a cast member of the soap opera Another World, playing architect Roy Bingham. After several small roles in dramas, he starred in Marie (1985), a film adaptation of Marie: A True Story by Peter Maas; he portrayed Charles Traughber. He also appeared in the miniseries The Atlanta Child Murders. Freeman also had a small role in the drama That Was Then... This Is Now, based on the novel of the same name by S. E. Hinton. In the mid-1980s, he began accepting prominent supporting roles in feature films, earning him a reputation for depicting wise, fatherly characters. In addition to television films, in 1987, Freeman played a violent street hustler, a role that diverged from his previous roles, in Street Smart co-starring Christopher Reeve and Kathy Baker.
== Properties == PAW contains reactive oxygen and nitrogen species, with a pH lower than untreated water along with higher electrical conductivity. PAW has disinfective properties: the oxidative stress that it causes on the cell membranes of the bacterial cells results in disruption of the cell membrane, followed by further damage that leads to cell death.
== Products and services == Access Control Systems Industrial and Commercial Fire Safety Consumer and Residential Fire Safety Hazard Sensing and Combustion Control Electronic Security Commercial Refrigeration Transport Refrigeration Heating, Ventilating, Air Conditioning Monitoring and Response Physical Security Cash in Transit Security Personnel Intrusion sensors Digital Video
== Additional sources == Birkhead T, Wimpenny J; Montgomerie B (2014). Ten Thousand Birds: Ornithology since Darwin. Princeton University Press. ISBN 978-0-691-15197-7. Chansigaud, Valerie (2009). History of Ornithology. London: New Holland Publishers. ISBN 978-1-84773-433-4. Gurney, John Henry (1921). "Early annals of ornithology". Nature. 108 (2713): 268. Bibcode:1921Natur.108..268.. doi:10.1038/108268a0. hdl:2027/coo.31924090299532. S2CID 4033666. Retrieved 19 November 2010. Newton, Alfred (1884). Ornithology. [S.l. : s.n.(Reprinted from the 1884 Encyclopædia Britannica) Podulka, Sandy; Eckhardt, Marie; Otis, Daniel (2001). "Birds and Humans: A Historical Perspective". In Podulka, Sandy; Rohrbaugh, Ronald W.; Bonney, Rick (eds.). Handbook of Bird Biology (2nd ed.). Ithaca, NY: Cornell Lab of Ornithology. pp. H1–H42. ISBN 978-0-938027-62-1. Walters, Michael (2005). A Concise History of Ornithology. New Haven, CT: Yale University Press. ISBN 978-1-84773-433-4.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.